Analogic debuted several new enhancements to its DASM-Rx family of connectivity productsthat improve their ability to interface with Fuji computed radiographyreaders. Analogic, of Peabody, MA, announced the new productsat last month's International
Analogic debuted several new enhancements to its DASM-Rx family of connectivity productsthat improve their ability to interface with Fuji computed radiographyreaders. Analogic, of Peabody, MA, announced the new productsat last month's International Society for Optical Engineeringmeeting in San Diego. The DASM-Rx line was unveiled by Analogicat last year's Radiological Society of North America meeting.
Analogic's Quality Assurance Workstation allows radiologiststo review CR images before sending them to a laser imager foroutput. The workstation supports up to two Fuji CR systems andis the first in a series of quality-assurance workstations Analogicis developing for the DASM-Rx line.
The company's CR Resource Gateway System, DASM-RGS-CR, providesFuji CR users with connectivity to a PACS or laser imager network.The product connects up to three Fuji CR systems per gateway.
Analogic's CR Resource Gateway Module, DASM-RGM-CR, enablesa systems integrator to acquire images from a Fuji CR reader withimage quality that matches that of Fuji CR film, according tothe company.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.